Preventing Bleeding With Direct-Acting Oral Anticoagulants
- PMID: 34649705
- PMCID: PMC10631742
- DOI: 10.1016/j.jacc.2021.06.056
Preventing Bleeding With Direct-Acting Oral Anticoagulants
Comment in
-
Reply: Preventing Bleeding With Direct-Acting Oral Anticoagulants.J Am Coll Cardiol. 2021 Oct 19;78(16):e129. doi: 10.1016/j.jacc.2021.07.059. J Am Coll Cardiol. 2021. PMID: 34649706 No abstract available.
Comment on
-
Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants.J Am Coll Cardiol. 2021 Jun 22;77(24):2987-3001. doi: 10.1016/j.jacc.2021.04.061. J Am Coll Cardiol. 2021. PMID: 34140101
References
-
- Gómez-Outes A, ALcubiLLa P, CaLvo-Rojas G, et al. Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants. J Am Coll Cardiol. 2021;77(24):2987–3001. - PubMed
-
- Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2288–2295. - PubMed
-
- Shin H, Cho MC, Kim RB, et al. Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation. J Thromb Thrombolysis. 2018;45(2): 250–256. - PubMed
-
- Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014;63(20):2141–2147 - PubMed
